Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Compounded peptides stories

Aug 10, 2026

Hims & Hers posts wider loss as shift to branded weight-loss drugs drives up costs

Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.

Aug 10, 2026·3 sources
00

Top claims

  • ▪The updated full-year revenue guidance for Hims & Hers Health Inc. includes contributions from Eucalyptus, an Australian digital health company it agreed to acquire in February
  • ▪Hims & Hers Health Inc. plans to enter the peptide market before the end of 2026 by selling allowed compounds including sermorelin and glutathione
  • ▪Hims & Hers Health Inc. stated that it expects to return to profitability in 2027

Subtopics

Corporate earnings1Digital health platforms1GLP-1 / Weight-Loss Medications1GLP-1 medications1Healthcare costs1Pharma1Pharmaceutical Industry1Weight management1

Related timelines

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories

Strait of Hormuz blockage

148 stories